Last reviewed · How we verify
Inhaled sedation with sevoflurane
Sevoflurane is a volatile anesthetic that depresses central nervous system activity by enhancing inhibitory GABA signaling and inhibiting excitatory glutamate signaling, producing sedation and anesthesia.
Sevoflurane is a volatile anesthetic that depresses central nervous system activity by enhancing inhibitory GABA signaling and inhibiting excitatory glutamate signaling, producing sedation and anesthesia. Used for Induction and maintenance of general anesthesia, Sedation in intensive care settings, Procedural sedation.
At a glance
| Generic name | Inhaled sedation with sevoflurane |
|---|---|
| Also known as | Experimental |
| Sponsor | University Hospital, Clermont-Ferrand |
| Drug class | Volatile anesthetic |
| Target | GABA-A receptor, NMDA glutamate receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation |
| Phase | Phase 3 |
Mechanism of action
Sevoflurane is a halogenated ether volatile anesthetic that acts on multiple ion channels and receptors in the central nervous system. It enhances the activity of inhibitory GABA-A receptors while simultaneously inhibiting excitatory NMDA glutamate receptors, resulting in rapid onset of sedation and anesthesia. When inhaled, it is absorbed through the lungs and rapidly distributes to the brain, producing dose-dependent depression of consciousness.
Approved indications
- Induction and maintenance of general anesthesia
- Sedation in intensive care settings
- Procedural sedation
Common side effects
- Postoperative nausea and vomiting
- Emergence delirium
- Airway irritation
- Hypotension
- Bradycardia
- Hepatotoxicity (rare)
Key clinical trials
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Sevoflurane's Effect on Neurocognition Study (EARLY_PHASE1)
- General Anesthesia Versus Sedation By Dexmedetomidine and Ketamine With Local Infiltration for Percutaneous Transcatheter Closure of Atrial Septal Defect in Pediatric Patients (NA)
- SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival (PHASE3)
- Evaluate the Protective Effect of Conditioning With Sevoflurane on the Myocardium (PHASE4)
- Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2 (NA)
- The Effect of Sedoanalgesia and General Anaesthesia on Early Neurological Recovery in Acute Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (NA)
- GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: